VITA 34 (0NLV) AI Stock Analysis

VITA 34

(LSE:0NLV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring biobanking revenueThe combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.

Negative Factors

Ongoing net lossesPersistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.

VITA 34 (0NLV) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 48.46M
Dividend Yield: ―
Average Volume (3M): 163
Price to Earnings (P/E): -6.4
Beta (1Y): 0.42
Revenue Growth: 0.06%
EPS Growth: 22.85%
Country: UK
Employees: 723
Sector: General
Sector Strength: 55
Industry: Biotechnology

VITA 34 Business Overview & Revenue Model

Company Description

VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therape...

VITA 34 Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0NLV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:MED	64Neutral	EUR 251.75M	8.72	11.54%	0.75%	2.94%	-14.28%
DE:SBS	57Neutral	EUR 273.51M	-562.50	-0.17%	2.67%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:ILM1	55Neutral	EUR 269.85M	24.05	2.16%	―	9.88%	-38.44%

* General Sector Average

Performance Comparison

GB:0NLV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0NLV	VITA 34	2.74	-2.31	-45.74%
DE:MED	MEDICLIN AG	5.30	1.68	46.37%
DE:SBS	STRATEC Biomedical	22.50	0.32	1.43%
DE:ILM1	Medios AG	10.58	-1.86	-14.95%
DE:HAEK	HAEMATO AG	12.70	3.43	36.99%
DE:7V0	Novogenia Holding AG	6.40	-0.54	-7.78%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

VITA 34 AI Stock Analysis